Dr Lal PathLabs Ltd (DLPL IN): Here’s Why Growth to Accelerate and Margin to Improve
Dr Lal PathLabs sees strong start to FY26 with double-digit growth driven by volume expansion resulting from expanding geographic presence. The...
564 Views
Dr. Lal Pathlabs: Focus on volume-led growth and margin. Maintain ADD
The company is focusing on innovation, including new wellness packages and high-end, super-specialty tests, with a focus on capturing prescription...
237 Views
Thematic Report on India Diagnostics: The Great Consolidation and the Rise of Organized Chains
Indian diagnostic sector shifts focus from pandemic testing to sustainable growth drivers, with listed players poised to gain market share from...
212 Views
Indonesia Strategy - Caught in a Perfect Updraft?
Despite the JCI knocking on all-time highs, valuations continue to look attractive with prospects of a better 2H2024 and lower interest rates. Top...
632 Views
Prodia (PRDA IJ) - Back to Core Testing
Prodia (PRDA IJ) FY2022 results saw declines in revenues and profits but from a COVID-high base and the numbers are now well-above 2019, with...
608 Views